Abstract: The control problem of dynamic systems that undergo sudden changes and rely on past data is known to be challenging to solve and has received a lot of attention in the past years. Meanwhile, ...

Abstract: In this article, we propose a computationally and communicationally efficient approach for decision-making in nonequilibrium stochastic games. In particular, due to the inherent complexity ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

CBSE Class 10 Maths Chapter 3: Pair of Linear Equations in Two Variables is a high-weightage chapter that helps students build strong algebraic and graphical problem-solving skills. This chapter ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...